Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors

NCT02078843 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

54

Enrollment

OTHER

Sponsor class

Stopped Superiority of one imaging method

Conditions

Gastroenteropancreatic Neuroendocrine Tumors

Interventions

DRUG: Gallium-68-DOTATATE PET/CT (index test)
DRUG: Indium-111-Octreoscan (standard test)

Sponsor

Insel Gruppe AG, University Hospital Bern

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]